Formulary Search Results for: CALCIUM AND VITAMIN D
11.8.1.3 Sodium hyaluronate preparations - View Category
Restrictions:
Restricted to use in severe dry eyes when Blink Intensive Tears or Eyeaze are not appropriate and the addition of trehalose is desirable (corneal damage).
Prescribing Notes:
- Contains sodium hyaluronate (0.15%) and trehalose (3%)
- Preservatives: preservative-free
15.1.4.2 Non-opioid analgesics - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
In June 2013, the MHRA issued new contraindications and warnings for diclofenac following a review of the cardiovascular risk, which it states is similar to that of the selective COX-2 inhibitors. A summary of the guidance on the MHRA website is available HERE
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use only for the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use only in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate, or have failed and who are considered unsuitable for biologic therapy given they current disease state or personal preference,
13.3 Local anaesthetics and antipruritics - View Category
Restrictions:
Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. Restricted to in-centre haemodialysis use only, in patients with an inadequate response to best supportive care for reducing itch.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with local guidelines for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.
Prescribing Notes:
Following a MHRA review in April 2023, the risk of increased incidence of malignancy, major adverse cardiovascular events (MACE), serious infections, venous thromboembolism (VTE) and mortality, when compared to those treated with tumour necrosis factor (TNF)-alpha inhibitors, were are considered a class effects across JAK inhibitors used for chronic inflammatory disorders and therefore it is advised to avoid prescribing these medicines unless there are no suitable alternatives in patients with the following risk factors:
- age 65 years or older
- current or past long-time smoking
- other risk factors for cardiovascular disease or malignancy
Please see further details of the review here.
8.3.2 Progestogens - View Category
3.1.2.1 Antimuscarinic combination inhalers - View Category
3.7 Mucolytics - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Responsibility for initiation, review and any necessary monitoring rests with specialist service.